Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

Purpose: Only a minority of patients with advanced non–small cell lung cancer (NSCLC) truly benefits from single-agent PD-1 checkpoint blockade, and more robust predictive biomarkers are needed. Experimental Design: We assessed tumor samples from 67 immunotherapy-treated NSCLC cases represented in a tissue microarray, 53 of whom had pretreatment samples and received monotherapy. Using GeoMx Digital Spatial Profiling System (NanoString Technologies), we quantified 39 immune parameters simultaneously in four tissue compartments defined by fluorescence colocalization [tumor (panCK+), leucocytes (CD45+), macrophages (CD68+), and nonimmune stroma]. Results: A total of 156 protein variables were generated per case. In the univariate unadjusted analysis, we found 18 markers associated with outcome in spatial context, five of which remained significant after multiplicity adjustment. In the multivariate analysis, high levels of CD56 and CD4 measured in the CD45 compartment were the only markers that were predictive for all clinical outcomes, including progression-free survival (PFS, HR: 0.24, P = 0.006; and HR: 0.31, P = 0.011, respectively), and overall survival (OS, HR: 0.26, P = 0.014; and HR: 0.23, P = 0.007, respectively). Then, using an orthogonal method based on multiplex immunofluorescence and cell counting (inForm), we validated that high CD56+ immune cell counts in the stroma were associated with PFS and OS in the same cohort. Conclusions: This pilot scale discovery study shows the potential of the digital spatial profiling technology in the identification of spatially informed biomarkers of response to PD-1 checkpoint blockade in NSCLC. We identified a number of relevant candidate immune predictors in spatial context that deserve validation in larger independent cohorts.

[1]  J. Taube,et al.  PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[2]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[3]  G. Kochan,et al.  Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy , 2019, EMBO molecular medicine.

[4]  K. Syrigos,et al.  High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling , 2019, Clinical Cancer Research.

[5]  Merrick I Ross,et al.  Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.

[6]  Wei Huang,et al.  A Colorful Future for Quantitative Pathology: Validation of Vectra Technology Using Chromogenic Multiplexed Immunohistochemistry and Prostate Tissue Microarrays , 2012 .

[7]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[8]  I. Wistuba,et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.

[9]  Sean C. Bendall,et al.  Systemic Immunity Is Required for Effective Cancer Immunotherapy , 2017, Cell.

[10]  R. Herbst,et al.  Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis , 2019, Clinical Cancer Research.

[11]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[12]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[13]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[14]  David L Rimm,et al.  Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[15]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[16]  Ayham A. Zaitouny,et al.  Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment , 2019, Science Translational Medicine.

[17]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[18]  R. Herbst,et al.  Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy , 2019, Clinical Cancer Research.

[19]  R. Herbst,et al.  Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes , 2019, Clinical Cancer Research.

[20]  Reinhard Dummer,et al.  High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Network Boston.

[21]  A. Chinnaiyan,et al.  Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[22]  C. Sima,et al.  Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.